Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05746143 · ClinicalTrials.gov registry record · Phase 4

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

A Phase 4 study of Pain, Postoperative and Lumbar Spine Degeneration, sponsored by University of Southern California.

Recruiting
Registry status
Phase 4
Development phase
140
Enrollment target
1
Study location

NCT05746143 is a Phase 4 study of Pain, Postoperative and Lumbar Spine Degeneration that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 140 participants, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05746143, a Phase 4 study of Pain, Postoperative and Lumbar Spine Degeneration, is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
Phase 4
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.

Interventions

  • DRUG Placebo
  • DRUG Zolpidem Tartrate 10 mg

Study Locations (1)

California

  • Keck Medical Center of USC - Los Angeles

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2022-02-01
Est. Completion 2027-12-31
Phase Phase 4

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT05746143

The ClinicalTrials.gov registry entry for NCT05746143 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (48% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Pain, Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05746143 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05746143 about?

NCT05746143 is a clinical study titled "The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion". The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.

What is the current status of trial NCT05746143?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2022-02-01. Estimated completion is 2027-12-31.

What conditions does trial NCT05746143 study?

This clinical trial studies the following conditions: Pain, Postoperative, Lumbar Spine Degeneration, Spine Fusion, Lumbar Spine Spondylosis.

What interventions are being tested in trial NCT05746143?

The interventions under investigation include: Placebo (DRUG), Zolpidem Tartrate 10 mg (DRUG).

Who is sponsoring clinical trial NCT05746143?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05746143 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.